



भारतीय जीवन बीमा निगम
LIFE INSURANCE CORPORATION OF INDIA

Ref. No.: LIC/SE/2022-23/41

Date: July 25th, 2022

To,

The Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Tower
Dalal Street
Mumbai – 400001

The Manager
Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot C/1,
G Block, Bandra Kurla Complex
Mumbai - 400051

ScripCode: (BSE - 543526/ NSE - LICI)

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Sale of Shares


Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that Corporation's shareholding in "SUN PHARMACEUTICALS INDUSTRIES LTD" has diluted from 16,85,66,486 to 12,05,24,944 Equity Shares decreasing its shareholding from 7.026% to 5.024% of the paid-up capital of the said Company.

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 are enclosed as "Annexure - A".

This is for your information and dissemination.

Yours faithfully,

For Life Insurance Corporation of India


(Pawan Agrawal)
Company Secretary & Compliance Officer

केन्द्रीय कार्यालय, "योगक्षेम", जीवन बीमा मार्ग, मुंबई - 400 021.
दूरभाष : 66598000

Central office, "Yogakshema", Jeevan Bima Marg, Mumbai - 400 021,
Tel.: 66598000

Annexure-A

SL No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	SUN PHARMACEUTICALS INDUSTRIES LTD. Market Cap – INR 2,08,106 Cr.
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group / group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	No
3	Industry to which the entity being acquired belongs	Pharmaceuticals Industry
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Investment Function. In ordinary Course of transaction.
5	Brief details of any governmental or regulatory approvals required for the acquisition.	NIL
6	Indicative time period for completion of the acquisition;	There is a decrease of 2% in holding during the period from 17.05.2021 to 22.07.2022.
7	Nature of consideration - whether cash consideration or share swap and details of the same.	Open Market Sale
8	Cost of acquisition or the price at which the shares are acquired;	Holding decreased from 7.026% to 5.024%, a decrease of 2.002% during the period from 17.05.2021 to 22.07.2022 at an average cost of INR 808.02
9	Percentage of shareholding / control acquired and / or number of shares acquired;	5.024%
10	Brief background about the entity acquired in terms of products / line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	The Company is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs).



EXECUTIVE DIRECTOR (INVT/BACKOFFICE)